<SEC-DOCUMENT>0000950170-24-122771.txt : 20241107
<SEC-HEADER>0000950170-24-122771.hdr.sgml : 20241107
<ACCEPTANCE-DATETIME>20241107070508
ACCESSION NUMBER:		0000950170-24-122771
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20241101
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241107
DATE AS OF CHANGE:		20241107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		241433090

	BUSINESS ADDRESS:	
		STREET 1:		919 EAST HILLSDALE BOULEVARD
		STREET 2:		SUITE 250
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		919 EAST HILLSDALE BOULEVARD
		STREET 2:		SUITE 250
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>gern-20241101.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-11-06T20:54:19.8496+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:gern="http://www.geron.com/20241101" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_42085f00-aa06-4225-ada9-3af899215f34" name="dei:AmendmentFlag" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_ad4adf5f-24bc-467d-8524-ef8f04e74cab" name="dei:EntityCentralIndexKey" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f">0000886744</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="gern-20241101.xsd"/></ix:references><ix:resources><xbrli:context id="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1.1in;width:6.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:1.1in;"><div style="z-index:-3;min-height:1in;position:relative;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">___________</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19a16dcf-e82c-4736-a3d8-f6a90ae536a4" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PURSUANT TO SECTION 13 OR 15(d) OF THE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES EXCHANGE ACT OF 1934</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1f7e529-1d71-40ca-816d-84523cf741af" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 1, 2024</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d225a95-eeff-4a72-809c-98624a0eb22a" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:33.333%;box-sizing:content-box;"/>
     <td style="width:33.333%;box-sizing:content-box;"/>
     <td style="width:33.333%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7e04af0a-ed41-4fc1-821a-355d3c556edb" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_26a06eb9-331b-41be-bfe6-5c9b537dae6f" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">000-20859</span></ix:nonNumeric></span></p></td>
     <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_46d2c521-64a1-46bc-8a0c-0a6cbaaf6458" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">75-2287752</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(State or other jurisdiction of incorporation)</span></p></td>
     <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(IRS Employer Identification No.)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df1483ff-6447-4800-98d8-55cfaf47972b" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">919 E. HILLSDALE BLVD</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">., </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d4d85ea-3c05-4fea-a463-8e7c0543ac2a" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SUITE 250</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0fdfa332-47c0-497d-8084-1f9ca7128a89" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FOSTER CITY</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae282c90-a710-4e42-9b23-2d4f1dc6c638" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LIFORNIA </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bef39178-9cc1-46e4-9b8c-723511bb7f7e" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94404</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Address of principal executive offices, including zip code)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51f874be-5ca8-4652-acbb-15289de79766" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7d8fb00-fcc5-4353-9a32-c6812a240348" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">473-7700 </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">N/A</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Former name or former address, if changed since last report)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></p><p style="text-indent:-4.132%;padding-left:3.968%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_bca1c177-6928-4b8b-ba22-a0a9912bffae" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:WrittenCommunications" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p><p style="text-indent:-4.132%;padding-left:3.968%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_349d26fc-390e-496a-a274-c6682436be67" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:SolicitingMaterial" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="text-indent:-4.132%;padding-left:3.968%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_4292de9f-c549-4343-b227-85f6a9236ba5" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="text-indent:-4.132%;padding-left:3.968%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_0240a386-cc42-4c5e-aa36-a7e3284276c5" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:33.34%;box-sizing:content-box;"/>
     <td style="width:22.22%;box-sizing:content-box;"/>
     <td style="width:44.44%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.075in;"><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title of each class</span></p></td>
     <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trading Symbol(s)</span></p></td>
     <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_5e2de6e6-8dc9-4d6c-b9c5-01528d2ddfef" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, $0.001 par value</span></ix:nonNumeric></span></p></td>
     <td style="border-right:0.5pt solid #000000;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.075in;"><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_0dc89aab-cbfc-4a03-a65d-1e54c24beed9" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GERN</span></ix:nonNumeric></span></p></td>
     <td style="border-right:0.5pt solid #000000;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.075in;"><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_839bd2b0-33fa-46d6-ba05-239a91477129" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company  </span><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_c05722e6-99cc-42b4-b777-10822eb3ab24" contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="eolpage2"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1.1in;width:6.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1.1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1.1in;width:6.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:1.1in;"><div style="z-index:-3;min-height:1in;position:relative;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:16.34%;box-sizing:content-box;"/>
     <td style="width:83.66%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 1.01</span></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Entry into a Material Definitive Agreement.</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.83%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pharmakon Loan Agreement</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 1, 2024, Geron Corporation (&#8220;we&#8221; or the &#8220;Company&#8221;) entered into a loan agreement (the &#8220;Loan Agreement&#8221;) with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership (each, a &#8220;Lender&#8221;), which are investment funds managed by Pharmakon Advisors, LP, and BioPharma Credit PLC, as collateral agent, which provides for a 5-year senior secured term loan facility of up to $250.0 million, divided into three committed tranches: (i) a Tranche A Loan in an aggregate principal amount of $125.0 million (the &#8220;Tranche A Loan&#8221;) which was funded on November 1, 2024 (the &#8220;Tranche A Closing Date&#8221;); (ii) a Tranche B Loan in an aggregate principal amount of $75.0 million (the &#8220;Tranche B Loan&#8221;) which is available, subject to certain limited conditions, at the Company&#8217;s option; and (iii) a Tranche C Loan in an aggregate principal amount of $50.0 million (the &#8220;Tranche C Loan&#8221;, and together with the Tranche A Loan and the Tranche B Loan, collectively, the &#8220;Term Loans&#8221;) which is available to the Company upon reaching a specified trailing twelve-month RYTELO&#153; revenue milestone. The Tranche B Loan and the Tranche C Loan, once available, may be requested on or prior to December 31, 2025. A portion of the proceeds from the Tranche A Loan were used to repay, in full, all amounts owed ($86.5 million) under the Company&#8217;s existing loan and security agreement, dated as of September 30, 2020, as amended, with Hercules Capital, Inc. and Silicon Valley Bank, a Division of First-Citizens Bank &amp; Trust Company, which was terminated effective November 1, 2024. The remaining proceeds will be used to fund the Company&#8217;s general corporate and working capital requirements.</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Term Loans mature on November 1, 2029 (the "Maturity Date"). The Term Loans bear interest at a variable rate per annum equal to 5.75% plus three-month Secured Overnight Financing Rate (&#8220;SOFR&#8221;) with a SOFR floor of 3.00%. As of inception of the Tranche A Loan, the interest rate applicable to the Tranche A Loan was 10.32%. Interest is due and payable quarterly on the last day of each quarter with the first payment due on December 31, 2024. The Loan Agreement requires we pay an amount equal to 2.50% of the Lenders&#8217; total committed amount to fund the Term Loans, payable with respect to each Term Loan on the funding date of such Term Loan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may elect to prepay the Term Loans in part or in whole prior to the Maturity Date with such prepayments being subject to a prepayment premium equal to the principal amount so prepaid multiplied by 3% if made prior to the 3rd anniversary of the funding date of the applicable Term Loan, 2% if made on or after the 3rd anniversary of the funding date of the applicable Term Loan but prior to the 4th anniversary of the funding date of the applicable Term Loan, and 1% if made on or after the 4th anniversary of the funding date of the applicable Term Loan but prior to the Maturity Date. In addition to the prepayment premium, prepayments of any Term Loan prior to the 2nd anniversary of the funding date of such Term Loan are subject to a makewhole amount equal to the sum of all interest that would have accrued through such 2nd anniversary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our obligations under the Loan Agreement are secured by substantially all of our assets, including our intellectual property. Certain of our subsidiaries may, from time to time after the Tranche A Closing Date, be required to guarantee our obligations under the Loan Agreement and, in connection with such guarantee, pledge substantially all of their assets, including intellectual property, to secure such guarantee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Loan Agreement contains customary affirmative and restrictive covenants and representations and warranties. We and our subsidiaries are bound by certain affirmative covenants setting forth actions that are required during the term of the Loan Agreement, including, without limitation, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. There are no financial covenants. Additionally, we and our subsidiaries are bound by certain restrictive covenants setting forth actions that are not permitted to be taken during the term of the Loan Agreement, including, without limitation, (i) selling or disposing of assets, (ii) amending, modifying or waiving our rights under material agreements, (iii) consummating change in control transactions unless all amounts becoming due under the Loan Agreement are paid in full immediately upon (and concurrent with) the consummation of any such change in control transaction, (iv) incurring additional indebtedness, (v) incurring non-permitted liens or encumbrance on our or our subsidiaries&#8217; assets, (vi) paying dividends or making any distribution or payment on or redeeming, retiring or purchasing any equity interests, and (vii) making payments on subordinated indebtedness, in each case, subject to specified</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1.1in;width:6.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1.1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1.1in;width:6.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:1.1in;"><div style="z-index:-3;min-height:1in;position:relative;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exceptions. The Loan Agreement also contains the following events of default: (i) failure to pay principal, interest and other amounts when due, (ii) the breach of the covenants under the Loan Agreement, (iii) the occurrence of a material adverse change or a withdrawal event in respect of RYTELO, (iv) certain attachments of the credit parties assets and restraints on their business, (v) certain insolvency, liquidation, bankruptcy or similar events, (vi) certain cross-default of third-party indebtedness and royalty revenue contracts, (vii) the failure to pay certain judgements, (viii) material misrepresentations, (ix) the loan documents ceasing to create a valid security interest in a material portion of the collateral, (x) the occurrence of certain ERISA events and (xi) the occurrence of a default under any subordination or intercreditor agreement, in each case subject to the grace periods, cure period and thresholds as specified in the Loan Agreement. Upon the occurrence of an event of default, the Lenders may, among other things, accelerate the Company&#8217;s obligations under the Loan Agreement (including all obligations for principal, interest and any applicable makewhole and prepayment premiums); provided that upon an event of default relating to certain insolvency, liquidation, bankruptcy or similar events, all outstanding obligations will be immediately accelerated.</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2.4pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.83%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Royalty Pharma Revenue Participation Right Purchase Agreement</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 1, 2024, we entered into a revenue participation right purchase and sale agreement (the &#8220;Royalty Pharma Agreement&#8221;) with Royalty Pharma Development Funding, LLC (&#8220;Royalty Pharma&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Royalty Pharma Agreement, we received an upfront payment of $125.0 million (the &#8220;Purchase Price&#8221;) in exchange for which Royalty Pharma obtained the right to receive tiered revenue interest payments with respect to U.S. net sales of RYTELO beginning on July 1, 2024, ranging from (i) 7.75% of annual U.S. net sales up to $500.0 million; (ii) 3.0% of annual U.S. net sales in excess of $500.0 million but less than or equal to $1.0 billion; and (iii) 1.0% in respect of annual U.S. net sales in excess of $1.0 billion (the &#8220;Revenue Interest Payments&#8221;). The Revenue Interest Payments to Royalty Pharma are capped, such that they will cease upon reaching a multiple of 1.65 times the Purchase Price if Royalty Pharma receives Revenue Interest Payments in that amount in respect of net sales occurring on or before June 30, 2031, or upon reaching a multiple of 2.0 times the Purchase Price thereafter. The Company&#8217;s revenue payment obligations under the Royalty Pharma Agreement may be discharged in connection with a change of control of the Company in an amount equal to 1.65 times the Purchase Price minus the aggregate Revenue Interest Payments received by Royalty Pharma as of the date of the closing of the change of control, if the closing of the change of control occurs on or prior to December 31, 2027, or in an amount equal to 2.0 times the Purchase Price minus the aggregate Revenue Interest Payments received by Royalty Pharma as of the date of the closing of the change of control, if the closing of the change of control occurs after December 31, 2027. There are no other royalties payable on RYTELO, which was developed internally and is exclusively owned by Geron.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Royalty Pharma Agreement contains customary representations, warranties and indemnities of Geron and Royalty Pharma and customary covenants relating to the Revenue Interest Payments.</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The foregoing descriptions of the Loan Agreement and the Royalty Pharma Agreement do not purport to be complete and are qualified in their entirety by reference to the complete text of the Loan Agreement and the Royalty Pharma Agreement, copies of which we expect to file, with confidential terms redacted, with the U.S. Securities and Exchange Commission as exhibits to our annual report on Form 10-K for the fiscal year ending on December 31, 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:16.34%;box-sizing:content-box;"/>
     <td style="width:83.66%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 1.02</span></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Termination of a Material Definitive Agreement.</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:16.34%;box-sizing:content-box;"/>
     <td style="width:83.66%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 2.01</span></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Completion of Acquisition or Disposition of Assets.</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information in Item 1.01 relating to the Royalty Pharma Agreement is incorporated by reference into this Item 2.01.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1.1in;width:6.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1.1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1.1in;width:6.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:1.1in;"><div style="z-index:-3;min-height:1in;position:relative;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:9%;box-sizing:content-box;"/>
     <td style="width:91%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 2.02</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#160;Results of Operations and Financial Condition</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.397%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 7, 2024, Geron Corporation (the "Company") issued a press release announcing its financial results for the three and nine months ended September 30, 2024 and recent business highlights. A copy of the press release is attached as Exhibit 99.1.</span></p><p style="text-indent:5.397%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.397%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in Item 2.02 and in the accompanying Exhibit 99.1 to this Current Report shall be deemed to be &#8220;furnished&#8221; and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and shall not be incorporated by reference into any filing made by the Company with the U.S. Securities and Exchange Commission under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></p><p style="text-indent:5.397%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:16.34%;box-sizing:content-box;"/>
     <td style="width:83.66%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 2.03</span></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</span></p></td>
    </tr>
   </table><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information set forth under Item 1.01 above is hereby incorporated by reference into Item 2.03.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:16.34%;box-sizing:content-box;"/>
     <td style="width:83.66%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 7.01</span></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial Statements and Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 7, 2024, the Company issued a press release announcing the Loan Agreement and the Royalty Pharma Agreement, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information furnished under Item 7.01 and in the accompanying Exhibit 99.2 to this Current Report shall be deemed to be &#8220;furnished&#8221; and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act,, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act, and shall not be incorporated by reference into any filing made by the Company with the U.S. Securities and Exchange Commission under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d)  Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.58%;box-sizing:content-box;"/>
     <td style="width:27.2%;box-sizing:content-box;"/>
     <td style="width:27.18%;box-sizing:content-box;"/>
     <td style="width:32.04%;box-sizing:content-box;"/>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="3" style="padding-left:0.02in;vertical-align:top;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-left:0.02in;vertical-align:top;padding-right:0.02in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit No.</span></p></td>
     <td colspan="3" style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="3" style="padding-left:0.02in;vertical-align:top;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-left:0.02in;vertical-align:top;padding-right:0.02in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
     <td colspan="3" style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press release titled "Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights," dated November 7, 2024</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="3" style="padding-left:0.02in;vertical-align:top;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-left:0.02in;vertical-align:top;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.2</span></p></td>
     <td colspan="3" style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex99_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press release titled &#8220;Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors,&#8221; dated November 7, 2024</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="3" style="padding-left:0.02in;vertical-align:top;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-left:0.02in;vertical-align:top;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
     <td colspan="3" style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">document)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1.1in;width:6.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1.1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1.1in;width:6.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:1.1in;"><div style="z-index:-3;min-height:1in;position:relative;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURE</span></p><p style="margin-left:4.968%;text-indent:-9.112%;padding-left:7.937%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.952%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p><p style="margin-left:47.619%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:47.619%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6.06%;box-sizing:content-box;"/>
     <td style="width:24.24%;box-sizing:content-box;"/>
     <td style="width:8.08%;box-sizing:content-box;"/>
     <td style="width:7.08%;box-sizing:content-box;"/>
     <td style="width:54.54%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;November 7, 2024</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">/s/ Scott A. Samuels</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Scott A. Samuels</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</span></p></td>
     <td style="text-indent:252pt;vertical-align:top;"><p style="text-indent:-252pt;padding-left:252pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Vice President,</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="text-indent:252pt;vertical-align:top;"><p style="text-indent:-252pt;padding-left:252pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Legal Officer and</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="text-indent:252pt;vertical-align:top;"><p style="text-indent:-252pt;padding-left:252pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Secretary</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1.1in;width:6.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1.1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>gern-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="margin-left:396pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><img src="img50521483_0.jpg" alt="img50521483_0.jpg" style="width:126px;height:62px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Achieved $28.2 million in RYTELO&#153; (imetelstat) net product revenue in first full quarter of sales</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">FOSTER CITY, Calif.,</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> November 7, 2024</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">-- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2024 and recent business highlights.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;This has been a transformative year for Geron, following our first FDA approval and commercial launch of RYTELO in June. The initial full quarter of product revenue from our U.S. launch exceeded our expectations and demonstrates strong execution as a commercial company. These results also reflect the high unmet need in lower-risk MDS and the compelling value proposition of RYTELO for hematologists and patients, giving us confidence in future continued demand and momentum for RYTELO,&#x201d; said John A. Scarlett, M.D., Geron&#x2019;s Chairman and Chief Executive Officer. &#x201c;We were also pleased to announce this morning the completion of important synthetic royalty and debt financing transactions with Royalty Pharma and Pharmakon Advisors. We believe that the favorable terms in these transactions reflect the significant commercial potential of RYTELO and provide us with critical flexibility to fuel continued growth and invest in our future.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Recent Business Highlights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Strong execution in the first full quarter of U.S. launch, with net product revenue for RYTELO (imetelstat) of $28.2 million in the third quarter of 2024. </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In November 2024, completed synthetic royalty and debt financing transactions to strengthen our cash position and further solidify our balance sheet while providing strategic flexibility to invest in our future. We entered into a synthetic royalty agreement with Royalty Pharma providing $125 million of capital in exchange for tiered royalty payments. We also entered into a 5-year, senior term loan agreement with Pharmakon for up to $250 million, from which we have drawn a first tranche of $125 million, a portion of which was used to fully repay amounts owed under our existing loan with Hercules Capital, Inc. and Silicon Valley Bank ($86.5 million), which has now been terminated, with the ability to borrow another $125 million prior to the end of 2025, subject to specified conditions. </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Jim Ziegler appointed as Executive Vice President, Chief Commercial Officer in September 2024, to spearhead Geron&#x2019;s global commercial strategy and operations, lead the commercial organization and be responsible for driving growth of RYTELO. Mr. Ziegler brings more than 25 years of commercial experience in the biopharmaceutical industry, spanning leadership, strategic and operational roles in both large and smaller organizations.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">New data to be presented at upcoming American Society for Hematology (ASH) Annual Meeting highlights the potential of imetelstat in myeloid hematologic malignancies( please view </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ASH press release</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> for more details). </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Upcoming Milestones<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">We expect review of the Marketing Authorization Application (MAA) for RYTELO in lower-risk MDS by the Committee for Medicinal Products for Human Use (CHMP) could be completed in late 2024 or early 2025, with potential approval by the European Medicines Agency (EMA) in the first half of 2025. We are continuing to prepare for the potential launch of RYTELO in the EU, and subject to regulatory approval, are planning to commercialize RYTELO in select EU markets commencing in 2026. </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">We expect an interim analysis from the Phase 3 IMpactMF trial in patients with relapsed/refractory MF may occur in early 2026 (when approximately 35% of planned enrolled patients have died) and the final analysis may occur in early 2027 (when approximately 50% of planned enrolled patients have died), based on our most recent planning assumptions for enrollment and death rates in the trial.</font></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.11in;min-height:0.2in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="margin-left:396pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Third Quarter 2024 Financial Results</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">As of September 30, 2024, we had approximately $378.9 million in cash, cash equivalents, restricted cash and marketable securities. On a pro forma basis, including gross proceeds from the upfront payment under the Royalty Pharma Agreement and the first tranche of the Pharmakon loan and after repayment of our existing debt, we had approximately $542.4 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2024.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Net Loss</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For the three and nine months ended September 30, 2024, the Company reported a net loss of $26.4 million, or $0.04 per share, and $149.2 million, or $0.23 per share, respectively, compared to $44.8 million, or $0.08 per share and $132.2 million, or $0.23 per share, respectively, for the three and nine months ended September 30, 2023.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Revenues</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Total product revenue, net for the three and nine months ended September 30, 2024, was $28.2 million and $29.0 million, respectively.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Total net revenue for the three and nine months ended September 30, 2024, was $28.3 million and $29.5 million, respectively, compared to $164,000 and $214,000 for the same periods in 2023. The increase in revenue is due to product revenue from U.S. sales of RYTELO, which was available for prescribers to order from specialty distributors as of June 27, 2024.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Operating Expenses</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Total operating expenses for the three and nine months ended September 30, 2024, were $56.5 million and $183.1 million, respectively, compared to $47.8 million and $139.9 million for the same periods in 2023.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cost of goods sold was approximately $456,000 and $473,000 for the three and nine months ended September 30, 2024, respectively, which consisted of costs to manufacture and distribute RYTELO.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Research and development expenses for the three and nine months ended September 30, 2024, were $20.2 million and $80.3 million, respectively, and $29.4 million and $92.1 million, for the same periods in 2023. The decrease is primarily due to manufacturing and quality costs that were capitalized in the current period due to FDA approval of RYTELO, compared to being expensed in the prior period.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Selling, general and administrative expenses for the three and nine months ended September 30, 2024, were $35.9 million, and $102.4 million, respectively, and $18.4 million and $47.7 million for the same periods in 2023. The increase in selling, general and administrative expenses primarily reflects higher commercial launch expenses, and increases in headcount and related expenses in connection with the U.S. launch of RYTELO.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Interest income was $4.9 million and $14.4 million for the three and nine months ended September 30, 2024, respectively, compared to $5.0 million and $13.6 million for the same periods in 2023. The decrease in interest income for the three months ended September 30, 2024, compared to the same period in 2023 was due to a decrease in interest rates. The increase in interest income for the nine months ended September 30, 2024, compared to the same period in 2023, primarily reflects a larger marketable securities portfolio with the receipt of net cash proceeds from the underwritten offering completed in March 2024, as well as higher yields from recent marketable securities purchases.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Interest expense was $3.0 million and $9.8 million for the three and nine months ended September 30, 2024, respectively, compared to $2.1 million and $6.0 million for the same periods in 2023. The increase in interest expense primarily reflects rising interest rates.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.11in;min-height:0.2in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="margin-left:396pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">2024 Financial Guidance</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For fiscal year 2024, we expect total operating expenses to be in the range of approximately $260 million to $270 million, which includes non-cash items such as stock-based compensation expense, amortization of debt discounts and issuance costs, and depreciation and amortization.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Based on our current operating plans and assumptions, we believe that our existing cash, cash equivalents, and marketable securities (including the $250 million gross proceeds received under the Pharmakon loan and Royalty Pharma agreements), together with anticipated revenues from U.S. sales of RYTELO, will be sufficient to fund our projected operating requirements for at least the next 12 months from the date of this press release. We believe that our projected financial resources will be sufficient to support commercial launch of RYTELO in the U.S. and potential launch in the EU, complete the Phase 3 IMpactMF trial in relapsed/refractory MF, invest in supply chain redundancy for RYTELO, and fund our general working capital requirements.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Conference Call</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Geron will host a conference call at 8:00 a.m. ET on Thursday, November 7, 2024, to discuss business updates and third quarter financial results.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">A live webcast of the conference call and related presentation will be available on the Company&#x2019;s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company&#x2019;s website for 30 days.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Participants may access the webcast by registering online using the following link,  </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">https://events.q4inc.com/attendee/539655875</font></font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About RYTELO (imetelstat)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">RYTELO (imetelstat) is an FDA-approved oligonucleotide telomerase inhibitor for the treatment of adult patients with low-to-intermediate-1 risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). It is indicated to be administered as an intravenous infusion over two hours every four weeks.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">RYTELO is a first-in-class treatment that works by inhibiting telomerase enzymatic activity. Telomeres are protective caps at the end of chromosomes that naturally shorten each time a cell divides. In LR-MDS, abnormal bone marrow cells often express the enzyme telomerase, which rebuilds those telomeres, allowing for uncontrolled cell division. Developed and exclusively owned by Geron, RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Geron</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO&#153; (imetelstat) is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to reduce proliferation and induce death of malignant cells. To learn more, visit </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.geron.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> or follow us on </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">LinkedIn</font></font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About IMpactMF Phase 3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:21pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">IMpactMF is an open label, randomized, controlled Phase 3 clinical trial with registrational intent. The trial is designed to enroll approximately 320 patients with intermediate-2 or high-risk myelofibrosis (MF) who are relapsed after or refractory to prior treatment with a JAK inhibitor, also referred to as relapsed/refractory MF. Patients will be randomized to receive either imetelstat or best available therapy. The primary endpoint is overall survival (OS). Key secondary endpoints include symptom response, spleen response, progression free survival, complete remission, partial remission, clinical improvement, duration of response, safety, pharmacokinetics, and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.11in;min-height:0.2in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="margin-left:396pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:21pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">patient reported outcomes. IMpactMF is currently enrolling patients. For further information about IMpactMF, including enrollment criteria, locations and current status, visit</font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> ClinicalTrials.gov/NCT04576156.</font></font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:21pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">IMPORTANT SAFETY INFORMATION ABOUT RYTELO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">WARNINGS AND PRECAUTIONS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Thrombocytopenia</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">RYTELO can cause thrombocytopenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased platelets occurred in 65% of patients with MDS treated with RYTELO.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Monitor patients with thrombocytopenia for bleeding. Monitor complete blood cell counts prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer platelet transfusions as appropriate. Delay the next cycle and resume at the same or reduced dose, or discontinue as recommended.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Neutropenia</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">RYTELO can cause neutropenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased neutrophils occurred in 72% of patients with MDS treated with RYTELO.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Monitor patients with Grade 3 or 4 neutropenia for infections, including sepsis. Monitor complete blood cell counts prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer growth factors and anti-infective therapies for treatment or prophylaxis as appropriate. Delay the next cycle and resume at the same or reduced dose, or discontinue as recommended.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Infusion-Related Reactions</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">RYTELO can cause infusion-related reactions. In the clinical trial, infusion-related reactions occurred in 8% of patients with MDS treated with RYTELO; Grade 3 or 4 infusion-related reactions occurred in 1.7%, including hypertensive crisis (0.8%). The most common infusion-related reaction was headache (4.2%). Infusion-related reactions usually occur during or shortly after the end of the infusion.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Premedicate patients at least 30 minutes prior to infusion with diphenhydramine and hydrocortisone as recommended and monitor patients for one hour following the infusion as recommended. Manage symptoms of infusion-related reactions with supportive care and infusion interruptions, decrease infusion rate, or permanently discontinue as recommended.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Embryo-Fetal Toxicity</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">RYTELO can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with RYTELO and for 1 week after the last dose.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ADVERSE REACTIONS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Serious adverse reactions occurred in 32% of patients who received RYTELO. Serious adverse reactions in &gt;2% of patients included sepsis (4.2%) and fracture (3.4%), cardiac failure (2.5%), and hemorrhage (2.5%). Fatal adverse reactions occurred in 0.8% of patients who received RYTELO, including sepsis (0.8%).</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Most common adverse reactions (&#x2265;10% with a difference between arms of &gt;5% compared to placebo), including laboratory abnormalities, were decreased platelets, decreased white blood cells, decreased neutrophils, increased AST, increased alkaline phosphatase, increased ALT, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, and headache.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.11in;min-height:0.2in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="margin-left:396pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide, available at </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">https://pi.geron.com/products/US/pi/rytelo_pi.pdf</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Use of Forward-Looking Statements</font><font style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the &#x201c;safe harbor&#x201d; provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, include, without limitation, those regarding: (i) the Company&#x2019;s expectations about the U.S. launch of RYTELO, its execution as a commercial company, the high unmet need in lower-risk MDS, and the compelling value proposition of RYTELO for hematologists and patients; (ii) the Company&#x2019;s confidence in future continued demand and momentum for RYTELO; (iii) the Company&#x2019;s view that the terms in the recently closed synthetic royalty and debt financing transactions reflect the significant commercial potential of RYTELO and provide the Company with critical flexibility to fuel continued growth and invest in its future; (iv) the Company&#x2019;s expectations for the timing and completion of regulatory review and approval of RYTELO in the EU and, subject to regulatory approval, the Company&#x2019;s plans to commercialize RYTELO in select EU markets commencing in 2026; (v) that the interim analysis of IMpactMF is expected in early 2026 and the final analysis is expected in early 2027; (vi) the Company&#x2019;s projections and expectations regarding the sufficiency of its financial resources to fund its projected operating requirements for at least the next 12 months from the date of this release, including the sufficiency and use of the Company&#x2019;s financial resources to support specified activities, and the assumptions underlying such projections and expectations; (vii) the Company&#x2019;s projections for total operating expenses for fiscal 2024; (viii) that inhibiting telomerase activity aims to potentially reduce proliferation and induce death of malignant cells; (ix) that IMpactMF has registrational intent; and (x) other statements that are not historical facts, constitute forward-looking statements. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (a) whether Geron is successful in commercializing RYTELO (imetelstat) for the treatment of certain patients with LR-MDS with transfusion dependent anemia; (b) whether Geron overcomes potential delays and other adverse impacts caused by enrollment, clinical, safety, efficacy, technical, scientific, intellectual property, manufacturing and regulatory challenges in order to have the financial resources for and meet expected timelines and planned milestones; (c) whether regulatory authorities permit the further development of imetelstat on a timely basis, or at all, without any clinical holds; (d) whether any future safety or efficacy results of imetelstat treatment cause the benefit-risk profile of imetelstat to become unacceptable; (e) whether imetelstat actually demonstrates disease-modifying activity in patients and the ability to target the malignant stem and progenitor cells of the underlying disease; (f) that Geron may seek to raise substantial additional capital in order to continue the development and commercialization of imetelstat; (g) whether Geron meets its post-marketing requirements and commitments in the U.S. for RYTELO for the treatment of patients with LR-MDS with transfusion dependent anemia; (h) whether there are failures or delays in manufacturing or supplying sufficient quantities of imetelstat or other clinical trial materials that impact commercialization of RYTELO for the treatment of patients with LR-MDS with transfusion dependent anemia or the continuation of the IMpactMF trial; (i) that the projected timing for the interim and final analyses of the IMpactMF trial may vary depending on actual enrollment and death rates in the trial; (j) whether Geron stays in compliance with and satisfies its obligations under its debt and royalty financing agreements; and (i) whether the EMA will approve RYTELO for the treatment of patients with LR-MDS with transfusion dependent anemia and whether the FDA and EMA will approve imetelstat for other indications on the timelines expected, or at all. Additional information on the above risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron&#x2019;s filings and periodic reports filed with the Securities and Exchange Commission under the heading &#x201c;Risk Factors&#x201d; and elsewhere in such filings and reports, including Geron&#x2019;s quarterly report on Form 10-Q for the quarter ended June 30, 2024, and subsequent filings and reports by Geron. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Financial table follows.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.11in;min-height:0.2in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="margin-left:396pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">GERON CORPORATION</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:40%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:12%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:12%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:12.14%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:11.86%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td colspan="7" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="7" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td colspan="7" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Three Months Ended</font></p></td>
     <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="7" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Nine Months Ended</font></p></td>
     <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td colspan="7" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">September 30,</font></p></td>
     <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="7" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">September 30,</font></p></td>
     <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">(In thousands, except share and per share data)</font></p></td>
     <td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2024</font></p></td>
     <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2023</font></p></td>
     <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2024</font></p></td>
     <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2023</font></p></td>
     <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td colspan="3" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">(Unaudited)</font></p></td>
     <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">(Unaudited)</font></p></td>
     <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">(Unaudited)</font></p></td>
     <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">(Unaudited)</font></p></td>
     <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Revenues:</font></p></td>
     <td colspan="3" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;&#160;Product revenue, net</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">28,209</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">28,989</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;&#160;Royalties</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">62</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">164</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">468</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">214</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">28,271</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">164</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">29,457</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">214</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Operating expenses:</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;&#160;Cost of goods sold</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">456</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">473</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;&#160;Research and development</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">20,153</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">29,426</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">80,305</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">92,135</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;&#160;Selling, general and administrative</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">35,877</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">18,350</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">102,361</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">47,734</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Total operating expenses</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">56,486</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">47,776</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">183,139</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">139,869</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Loss from Operations</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(28,215</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(47,612</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(153,682</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(139,655</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Interest income</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">4,877</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">4,965</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">14,448</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">13,556</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Interest expense</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(3,046</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(2,066</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(9,798</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(5,991</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Other income and (expense), net</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(63</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(92</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(188</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(64</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Net loss</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(26,447</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(44,805</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(149,220</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(132,154</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Basic and diluted net loss per share:</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;&#160;Net loss per share</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(0.04</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(0.08</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(0.23</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(0.23</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;&#160;Shares used in computing net loss per share</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">662,158,182</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">579,508,305</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">639,933,612</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">562,445,577</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:67.093%;box-sizing:content-box;"></td>
     <td style="width:1.499%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:12.954%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.499%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:12.954%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">September 30,</font></p></td>
     <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">December 31,</font></p></td>
     <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">(In thousands)</font></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2024</font></p></td>
     <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2023</font></p></td>
     <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">(Unaudited)</font></p></td>
     <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">(Note 1)</font></p></td>
     <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Current assets:</font></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Cash, cash equivalents and restricted cash</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">62,198</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">71,138</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;Current marketable securities</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">279,430</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">263,676</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Other current assets</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">56,429</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">6,534</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">398,057</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">341,348</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Noncurrent marketable securities</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">37,312</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">43,298</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Property and equipment, net</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">1,595</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">1,177</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Deposits and other assets</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">7,986</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">8,253</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">444,950</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">394,076</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Current liabilities</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">137,933</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">108,070</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Noncurrent liabilities</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">14,733</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">38,057</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Stockholders&#x2019; equity</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">292,284</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">247,949</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">444,950</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">394,076</font></p></td>
     <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:-36pt;padding-left:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Note 1: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Derived from audited financial statements included in the Company&#x2019;s annual report on Form 10-K for the year ended December 31, 2023.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.11in;min-height:0.2in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="margin-left:396pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">CONTACT:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Aron Feingold</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Vice President, Investor Relations and Corporate Communications</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Kristen Kelleher</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Associate Director, Investor Relations and Corporate Communications</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">investor@geron.com</font></font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">media@geron.com</font></font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">#####</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.11in;min-height:0.2in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>gern-ex99_2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html>
 <head>
  <title>EX-99.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.2</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><img src="img51445004_0.jpg" alt="img51445004_0.jpg" style="width:126px;height:62px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Geron received $250 million in gross proceeds at closing, with access to an additional $125 million in debt</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Strengthens balance sheet to support the commercial launch of RYTELO&#153; in the U.S. and potential launch in the EU, the ongoing Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis, and other uses</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">FOSTER CITY, Calif.,</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> November 7, 2024</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">-- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced up to $375 million in synthetic royalty and debt financings with Royalty Pharma and investment funds managed by Pharmakon Advisors, LP, of which $250 million in cash was provided at closing and another $125 million in debt is available. The transactions are comprised of a $125 million synthetic royalty with Royalty Pharma and $250 million of committed senior secured debt with investment funds managed by Pharmakon Advisors, LP.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;The substantial financial commitment of exceptional long-term partners like Royalty Pharma and Pharmakon Advisors strengthens our cash position and further solidifies our balance sheet, while providing flexibility to invest in our future,&#x201d; said Michelle Robertson, Geron&#x2019;s Executive Vice President, Chief Financial Officer. &#x201c;We believe that the terms reflect the significant commercial potential of RYTELO. The proceeds are expected to enable us to support the commercial launch of RYTELO in the U.S. and potential launch in the EU, complete our Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis, invest in supply chain redundancy for RYTELO, and our general working capital requirements.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Royalty Pharma has provided $125 million at closing and will receive tiered royalty payments on U.S. net sales of RYTELO, ranging from 7.75% of annual net sales up to $500 million, 3.0% of annual net sales between $500 million and $1.0 billion, and 1.0% of annual net sales over $1 billion. Payments to Royalty Pharma will cease if the aggregate royalties payable through June 30, 2031 reach a multiple of 1.65 its investment, otherwise the royalty payments will continue until Royalty Pharma receives a multiple of 2.0 its investment. There are no other royalties payable on RYTELO, which was developed internally and is exclusively owned by Geron.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;RYTELO is an important therapy for the lower-risk MDS patient population, whom otherwise have limited options, and we look forward to its development in other hematologic malignancy indications. We are delighted to establish this partnership with Geron to help fuel their execution of significant commercial and development opportunities ahead,&#x201d; said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Investment funds managed by Pharmakon Advisors, LP have committed to a 5-year, senior secured term loan of up to $250 million, of which a first tranche of $125 million has been drawn at closing. A portion of these proceeds were used to fully repay amounts owned under the Company&#x2019;s existing loan with Hercules Capital, Inc. and Silicon Valley Bank ($86.5 million), which has been terminated. A second tranche of $75 million can be drawn at Geron&#x2019;s option, subject to certain limited conditions, and a third tranche of $50 million can be drawn at Geron&#x2019;s option upon reaching a specified RYTELO revenue milestone, in each case if requested prior to December 31, 2025. The facility contains no scheduled amortization payments, with all outstanding principal due at maturity in 2029, and there are no financial covenants. The loans bear interest at a variable rate per year equal to 5.75% plus the three-month Secured Overnight Financing Rate (SOFR), subject to a SOFR floor of 3.00%.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;The Geron team is driving commercial success in the U.S. with RYTELO, an innovative first-in-class telomerase inhibitor, and we look forward to supporting the company and management team as they plan for a potential launch in the EU and continue to develop the asset in additional hematologic malignancies,&#x201d; said Pedro Gonzalez de Cosio, Chief Executive Officer of Pharmakon Advisors, LP.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">TD Cowen served as financial advisor and Cooley LLP served as legal advisor to Geron. Goodwin Procter and Fenwick &amp; West LLP served as legal advisors to Royalty Pharma and Akin Gump LLP served as legal advisor to Pharmakon Advisors, LP.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Geron</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO&#153; (imetelstat) is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:468pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to reduce proliferation and induce death of malignant cells. To learn more, visit </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.geron.com</font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">or follow us on </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">LinkedIn</font></font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Use of Forward-Looking Statements</font><font style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the &#x201c;safe harbor&#x201d; provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, include, without limitation, those regarding: (i) the expected use of proceeds from the debt and synthetic royalty financings; (ii) projections and expectations regarding the sufficiency of the Company&#x2019;s financial resources to fund its projected operating requirements, including to support commercial launch of RYTELO in the U.S. and complete its Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis; (iii) the Company&#x2019;s plans for the potential launch of RYTELO in the EU, subject to regulatory approval; (iv) the developmental and commercial potential of RYTELO; and (v) other statements that are not historical facts, constitute forward-looking statements. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (a) whether Geron is successful in commercializing RYTELO (imetelstat) for the treatment of certain patients with LR-MDS with transfusion dependent anemia; (b) whether Geron overcomes potential delays and other adverse impacts caused by enrollment, clinical, safety, efficacy, technical, scientific, intellectual property, manufacturing and regulatory challenges in order to have the financial resources for and meet expected timelines and planned milestones; (c) whether regulatory authorities permit the further development of imetelstat on a timely basis, or at all, without any clinical holds; (d) whether any future safety or efficacy results of imetelstat treatment cause the benefit-risk profile of imetelstat to become unacceptable; (e) whether imetelstat actually demonstrates disease-modifying activity in patients and the ability to target the malignant stem and progenitor cells of the underlying disease; (f) that Geron may seek to raise substantial additional capital in order to continue the development and commercialization of imetelstat; (g) whether Geron meets its post-marketing requirements and commitments in the U.S. for RYTELO for the treatment of patients with LR-MDS with transfusion dependent anemia; (h) whether there are failures or delays in manufacturing or supplying sufficient quantities of imetelstat or other clinical trial materials that impact commercialization of RYTELO for the treatment of patients with LR-MDS with transfusion dependent anemia or the continuation of the IMpactMF trial; (i) that the projected timing for the interim and final analyses of the IMpactMF trial may vary depending on actual enrollment and death rates in the trial; (j) whether Geron stays in compliance with and satisfies its obligations under its debt and royalty financing agreements; and (i) whether the EMA will approve RYTELO for the treatment of patients with LR-MDS with transfusion dependent anemia and whether the FDA and EMA will approve imetelstat for other indications on the timelines expected, or at all. Additional information on the above risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron&#x2019;s filings and periodic reports filed with the Securities and Exchange Commission under the heading &#x201c;Risk Factors&#x201d; and elsewhere in such filings and reports, including Geron&#x2019;s quarterly report on Form 10-Q for the quarter ended June 30, 2024, and subsequent filings and reports by Geron. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">CONTACT:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Aron Feingold</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Vice President, Investor Relations and Corporate Communications</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Kristen Kelleher</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Associate Director, Investor Relations and Corporate Communications</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">investor@geron.com</font></font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">media@geron.com</font></font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">###</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img50521483_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img50521483_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -V!PX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBCM0!D:OK(TR6WB6+S99FP%SC ]?UK6]*X3[1_:_C*(]427">F
M$R?UQFN[Q7G8'$RQ$ZDOLIV1TXBDJ2BNMKL6BBBO1.8**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!*S-=O?L.DSR@X<C:GU/'_UZTZXSQI=
M[IH+-3PH,C#WZ#^M<&98CV&&E);G1A*?M*L8E7P?%YFLM(>B1DCZD@5WM<AX
M)C_X_)?]U1^N:Z^N?)(<N$3[W-,?*]=KL+1117KG&%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 G;->7ZM=?;-5N+@'*LQ"_0<#]!7H6L77
MV/2;F;."J$*?<\#]37F%?+\15_AI+U/7RNG\4SN/!:8TN9_[TQ_D*Z6L'PBN
MW04/]YV/Z_\ UJWJ]K+8\N%@O(X,4[UI>HM%%%=QSA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 <QXSN-FGPVX/,CY/T _Q(KB*Z'QC<>9J
ML<0/$48S]2?_ -5<]7P><5O:8N7EH?1X"'+07F>B>%@!X=MSZES_ ./&MFL?
MPO\ \BY:_P# _P#T,UL5]E@?]VI^B_(\&O\ Q9>K US?B'6_[.US0+)7VF\N
MB&'JH4KC\W7\JZ3%>*_$35_+^(=M(IXTX1' _O [\_J*]+"TO:SY?)G!BZWL
MJ:?FCVNBFJ0R@@Y!Y!%.KG.I!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFW0]SHJO9WMMJ%K'=6DR2PR#*NAR"*L5Y+33LSV$TU="T444#"BBB@ HHHH
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M)XET*0X36=/8^@N4/]:OP75O<KF&>*4>J.&_E2<9+= IQ>S)Z*,T4BPHHHH
M**** "BBB@ HHHH **** "BBB@ I*,@=Q5"YUG3+3_CYU&TAQU\R95_F::3>
MQ+DENR_16$_C/PY'G=K5D<''RS!OY4S_ (3GPS_T&;;_ +ZJO93_ )61[>G_
M #+[SH**QH_%?A^4X76K#/H;A!_6M*"\MKI=UO<12KZHX8?I2<)+=%*I&6S+
M%%&:*DL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHS0 E%0SW=O;+NFGBB'J[A?YU0?Q+H49P^LZ>I]#<H/ZTU&3V1#G
M%;LU:*R/^$I\/_\ 0<T[_P "H_\ &K46K:;.<1:A:R'T693_ %IN$ET!3@]F
M7J*0,I&0>*6I+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI1=IH]BAB:=97BRU1116!TA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 E%'2L_4]6MM+AWRMES]U!U;_ #ZTTFW9$RE&*YI&AW]JPO%B;M!E
M/]UD/Z__ %ZRM*U[4+_7(HF=1#(3F,*,  $]>O:M[Q#'YF@W:^B;OR.?Z5S9
MA2:P\XOLRL#7C4G&4>YYM1117YL?7!1113 ]-T:[^VZ3;S$Y8KAOJ.#_ "K0
MKC_!=YS/9,?^FBC]#_2NQK]"R^O[?#1F?,8FG[.K*)XO\6M(^S:[!J:+^[NX
M]KG_ &TP/U!'_?->>]J^@/'^C?VUX3ND1<S6_P"_B^JCD?B,BOGZOK\OK<]&
MSW1\GF-'DK774****[S@/:/A=XC_ +1TEM)N'S<V8_=YZM%V_(\?3%>A5\SZ
M#K$^@ZU;:A#R8F^=?[RG[P_*OI"RO(-0LH;NW</#,@=&'<&OGL?A_95.9;,^
MCR[$>TI\LMT6:***X#T0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M0D 9/2@ /2O-?&/Q+CLC)8:&R2W RKW/5(SZ+ZGWZ?6LCQ[\06OFETG1I<6O
M*S7"]9?55_V?4]_IU\VKU\'@+I3J_<>+C<PU<*7WDMQ<SW=P]Q<RO+-(<L[D
MLQ/N:BHHKV%H>+OJPHHJS96%YJ5P(+*UEGE/\,:%C]3Z"B4E%7813D[)%:BO
M1-(^$NIW(#ZG=16:'JB?O'^A[#\S79:?\,?#=D 98);QQ_%/(<9^BX'YUPU,
MPHPT6IW4LNKSU:MZGA.*DCMYI<>5"[Y.!M4GGTKZ6M="TFRQ]ETVTAQW2%0?
MSQ5_ ]*YGFO\L?Q.N.4/[4OP/E]M/OHUW-97"KZF)@/Y5 RM&VUE93Z$8-?5
M&!4<L,4J;9(T=?1E!%)9J^L?Q&\H727X'RS2YKZ.O/"'A^^4^?I%H2>K)&$8
M_BN#7,:E\(]'N58V-S<6;GH"?,4?@>?UK>&9TG\2:.>>5U5\+3/%Z*Z_6?AM
MK^E!I(X%OH!_%;99L>Z]?RS7(LI0E65@P."#P0:[:=6%17@[G#4HU*;M-6$H
MHHK4S"BBB@!\4,MQ/'!#&TDLA"HBC)+'H *]Y\$>$(O#&G^9,H?49P/.DZ[1
M_=!]/YG\*Y_X6^&;5;/^WI7CFN7+)$HY\@=#G_:/\OK7IU>%C\6Y/V<=CWLN
MP:C'VLMWL+1117F'K!1110 4444 %%%% "52U/5+31[%[R^F6*%.K$]3Z#U/
MM3-8UBTT/39+Z]?9#&.@Y+'L .Y->!>)_%%[XFOS/<-LMT)\FW!X0?U8]S77
MA<)*N[]#BQF,C0C9;FIXM\?WWB)WMK;?;:=T\L'YI!ZO_P#$]/K7'445]!2I
M0I1Y8(^<JU9U9<TF%%%.56D<(@9F8X50,DGT%:F=AM&*[31?AGKNJA9+E!80
M'O/G>1[+_CBNYTWX4:%:@&\>XO7[[GV+^ 7G]:XZN/HT]+W.RE@*]35*WJ>)
M4](I),[$9L=< FOI&T\,Z)8@?9M+M$(_B\H$_F>:U%154!5  Z 5R2S5?9B=
MD<HE]J7X'S#_ &;?XS]BN,=<^6W^%0/%)'C>C+GID$5]3X%-:-64AE4@]01Q
M4K-7UC^)3RA=)?@?*]+7TI>>&M%O@?M.E6DA/\1A7/YXS7-:C\*M O 3:^?9
M/V\M]ZY]PV?T(K6&:4W\2:,)Y557PM,\0X-)7<:S\+M;TX-)9E+^$?\ //Y7
MQ_NG^A-<5-#+;S/#-&\4J'#)("K ^A'6N^E6IU%>+N<%2A4I.TU891116ID:
M_A_Q'J/AV\\^QFPA_P!9"W*./<?UZU[EX7\66'BBS\RW/EW"#][;L?F4^WJ/
M>OG:K>FZE=:5?Q7ME*8IXCE6'?U!'<'N*XL5@XUE=:,[\)C9T'9ZQ/J"BN;\
M(^*[?Q1IOFJ!'=18$\.?NGU'L>U='7STX2A+EDCZ.$XSCS1>@M%%%26%%%%
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M?2/A[Q%8>(]/%U929Q@21M]Z-O0BMC%?-GA[Q#=^'-42]M6ROW98CTE7/3_
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MA:16MM&L<$2A41>@ JQ117SC=]6?2I)*R%HHHH&%%%% !1110 4444 %%%%
M!1110!S?B_PM!XGTHQ$*MW%EK>7T;T/L>]?/MS;36ES+;7$;1S1,4=#U!!Y%
M?4M>6?%;PT&1=?MH_F&([D#N.BL?IT_*O3R_$N,O9R>C/)S+"J4?:Q6J/***
M**]T\$T] UF;0M;MM0BY\IOG7^\I^\/RKZ1MKF*\M8KF!P\4J!T8="",@U\M
MU[+\)]:-YHDNERMF6R?*9ZF-B3^AS^E>5F="\5573<];*Z_+)TWU/1J***\0
M]X**** $KG_'/_(DZM_UP-=!7/\ CG_D2=6_ZX&M*/\ $CZHRK?PY>C/G6BB
MBOK#Y **** -#1-(N==U>#3[4?O)3RQZ*O=OIBOHG1M'M=#TR*PLTVQ1CKW8
M]V)[DUR'PN\.C3M%.JSIBZOAE,]5C[?GU_*O0*^>Q^)=2?+'9'T67854X<\M
MV+1117 >D%%%% !1110 4444 %%%% !1110!POQ(\,+K.CMJ%O'F^LE+#'5X
M^K+_ %'_ ->O#J^J2,U\\>-M$&@^*;JVC3;;R?OH1VVMV'T.1^%>SEE=O]U+
MY'AYIATFJL?F<[1117KGCG;?"_5SIWBD6C/B&^0QD=MXR5/\Q^->Z5\N6ES)
M97D%U"<2PR+(I_VE.1_*OIRTN$N[.&YB.8YHU=3[$9'\Z\+,Z?+44UU/>RJK
M>#@^A8HHHKS#U@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?@ZU9UQ+=9N'_P"!?=_\= KK:^9QE7VE9OHCZC TO9T4NKU%HHHKE.P****
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MYN9QO13[,]+*I6K-=T>A4445X)]$%%%% !1110 4444 %%%% !1110 4444
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M_P#V='_"F#_T'O\ R3_^SKU:BCZ_B/YOP0?V?A_Y?Q9Y3_PI@_\ 0>_\D_\
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M 4444 %%%% !114<DB0Q-)(P5%!9F/  [F@#ROXPZH"^GZ4K?=S<2#_QU?\
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MO]XC\_R/5Z***^</J HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAT;2;73X/]7!&$!]3W)^IYKS,RK\L%377\CT\LH<]3G>R-"BBBO"/H0HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 5RWB3XH:?IRM;Z3MOKKIO'^J4_7^+\./>O(M3U6^UB^:[O[AYIF[GH!Z =
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M_M5OK&:W;I(I /H>QKBIRY9)G1B*?M*;B>6T4Z5&BD:-QAT)5AZ$=:;7IGS
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MRV/I,-AH4(V6XM%%%<YTA1110 4444 ?/WQ'_P"1^U3ZQ?\ HI:Y6NJ^(_\
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M_P!=W_G7A?8U[I\*_P#D2X_^N[_SKSLS_@KU/1RK^/\ ([>BBBO /HPHHHH
M**** "BBB@ HHHH **** "BBB@!*J:K_ ,@F\_ZX/_Z":MU4U7_D$WG_ %P?
M_P!!-./Q(F?PL^8****^N6Q\:]PKU3X,?>UOZ0?^U*\KKU3X,?>UOZ0?^U*X
M\P_W=_+\SLR[_>(_/\CU>BBBOG#Z@**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^'WOTKF;BTN;.3R[F"6!_P"[*A4_D:[X583^%W//G1J0^)6(J***U,PHHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1=)MM/MQ\D*;<GJQ[D_4\UHT45XC;;NSWHI122%HHHI%!1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"8?V,-=WN+1117,=84444 %%%% !1110 4444 )7F'QBM"]EI=Z!Q'*\1/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJHJJJX4< #M3Z^[P6"AA::C'?JSYS$5Y5I\TA:***[3 **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU@BAB'18T"@?@*GHHS7->^YU)6T0M%%% PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *BEC6:%XVSM<%3C@X-244FDU9@0P6\5M&(H8U
M1%Z*HP*FHHH225D#;;NQ:***8!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img51445004_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img51445004_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -V!PX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBCM0!D:OK(TR6WB6+S99FP%SC ]?UK6]*X3[1_:_C*(]427">F
M$R?UQFN[Q7G8'$RQ$ZDOLIV1TXBDJ2BNMKL6BBBO1.8**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 G;->7ZM=?;-5N+@'*LQ"_0<#]!7H6L77
MV/2;F;."J$*?<\#]37F%?+\15_AI+U/7RNG\4SN/!:8TN9_[TQ_D*Z6L'PBN
MW04/]YV/Z_\ UJWJ]K+8\N%@O(X,4[UI>HM%%%=QSA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 <QXSN-FGPVX/,CY/T _Q(KB*Z'QC<>9J
ML<0/$48S]2?_ -5<]7P><5O:8N7EH?1X"'+07F>B>%@!X=MSZES_ ./&MFL?
MPO\ \BY:_P# _P#T,UL5]E@?]VI^B_(\&O\ Q9>K US?B'6_[.US0+)7VF\N
MB&'JH4KC\W7\JZ3%>*_$35_+^(=M(IXTX1' _O [\_J*]+"TO:SY?)G!BZWL
MJ:?FCVNBFJ0R@@Y!Y!%.KG.I!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFW0]SHJO9WMMJ%K'=6DR2PR#*NAR"*L5Y+33LSV$TU="T444#"BBB@ HHHH
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M)XET*0X36=/8^@N4/]:OP75O<KF&>*4>J.&_E2<9+= IQ>S)Z*,T4BPHHHH
M**** "BBB@ HHHH **** "BBB@ I*,@=Q5"YUG3+3_CYU&TAQU\R95_F::3>
MQ+DENR_16$_C/PY'G=K5D<''RS!OY4S_ (3GPS_T&;;_ +ZJO93_ )61[>G_
M #+[SH**QH_%?A^4X76K#/H;A!_6M*"\MKI=UO<12KZHX8?I2<)+=%*I&6S+
M%%&:*DL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHS0 E%0SW=O;+NFGBB'J[A?YU0?Q+H49P^LZ>I]#<H/ZTU&3V1#G
M%;LU:*R/^$I\/_\ 0<T[_P "H_\ &K46K:;.<1:A:R'T693_ %IN$ET!3@]F
M7J*0,I&0>*6I+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI1=IH]BAB:=97BRU1116!TA1110 4444 %%%% !1110 4444 %%%% !1110
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M(^*[?Q1IOFJ!'=18$\.?NGU'L>U='7STX2A+EDCZ.$XSCS1>@M%%%26%%%%
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M?2/A[Q%8>(]/%U929Q@21M]Z-O0BMC%?-GA[Q#=^'-42]M6ROW98CTE7/3_
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MA:16MM&L<$2A41>@ JQ117SC=]6?2I)*R%HHHH&%%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*:[+&C,QP ,DTZL;Q-=?9M
M%E ;#2D1C\>OZ TXJ[L9U9J$')]#A]1NVOK^:Y;^-OE'HHZ#\JJT45ZB5E9'
MR\FY-MA1113$CT_25V:3:#IB%/Y"KE5[!=EA;KZ1*/TJQ7E/<^J@K12.7\:P
M;K.VG'_+-RI^A'_UJXJO2?$-O]IT.Y7NJ[Q^!S_2O-J^*SZERXGF[H^ARV=Z
M7+V84445X1Z 4444 =-X/U#R;Q[-S\LOS)_O8Y_2NWKR6&9[>>.6(X="&4^X
MKU#3[M+ZQAN4Z.N<>A[U]AD.+YZ;HR>JV]#Q,QH<L^=;,34;"#4].GLKE=T,
MZ%&'L1_.OFS4]/FTK4[FPN!B6WD*,>F?0CV(Y%?3U>4_%KP]@P:[ G'$-QC_
M ,=8_P ORK[++J_)4Y'L_P SYG,\/SPYUNCRNBBBO?/G@KJ_ 'B+^P/$,8F;
M;9W6(YL]!S\K?A_+-<I2YJ*M.-2#A+J72J.G-370^J<TM<;\.O$/]N>'$BG;
M==V>(I,]2,?*WX@8^H-=C7RM2#IR<9=#ZVE452"G'J+1114&@4444 %%%% !
M1110 4444 )7C7Q=U(SZW9Z<K?);1&1A_M.>_P! !_WU7LM?.7C&\^W^+]5G
MSD>>T8/LGR_R%>AEM/FK7['FYI4Y:/*NIA4445] ?.B@$G Y)Z"OH_PIHPT+
MPY9V.,2*FZ4^KGEOUXKQ'P/IPU3QCIT##,:2><_IA!NY^I %?1 Z5XN:5=53
M1[>4TM'4?H+1117DGLA1110 4444 %%%% !1110 4444 %%%% !1110 G>O&
MOBUHPMM8M]5C3"7:^7)C^^O0GZC_ -!KV6N2^(^G"_\ !=X=N9+8B=/;:>?_
M !TFNG!U/9UHLY,=3]I0:['@5%%%?3GRP^.5X9EEC.UT(96'4$'(-?3&CZ@N
MJ:-9WR]+B%9,#L2,D?TKYDKW/X67INO!J1$Y-K,\7OC[W_LU>5FD+P4^QZN4
MSM4<.Z.XHHHKQ#WQ*CFE2""265MJ1J69CV &<U)7+_$*_-AX*U!E.'F40+_P
M(X/Z9JJ<>>:BNIG5GR0<GT/"=4U"35-6N[Z3[]Q*TF#S@$\#\!Q5.BBOK(I1
M22/CY-R;;%%=5\/=%&L>+(#(NZ"U'GN#T.#\OZXKE*]G^$FE_9O#]SJ##Y[N
M;"G_ &$X'ZEJYL=5]G1;74Z\#2]I729Z)1117S1]2%%%% !1110 4444 %%%
M% !1110 4444 %%%% "5X9\4M(_L_P 4_:T7$5Z@D]MXX;^A_&O<Z\^^+=@+
MCPU!> ?/:SCG_988/Z[:Z\!4Y*R\SAS"GST'Y:GBU%%%?2GS)T'@G4#IOC#3
M9LX1Y1"WIA_EY^F<U]%5\KQNT4BRH<.A#*?0CI7U#:7"W5E#<)]V2-7'T(S7
MB9K#WHS/<RF?NR@6****\H]@**** /G[XC_\C]JGUB_]%+7*UU7Q'_Y'[5/K
M%_Z*6N5KZG#?P8>B/D<3_&GZL*,4=JO:19_VAK-A9-]V>=(V^A89_2M9223;
M,HIMI(]X\#:2-'\)V4!7$LJ^?+Z[FYP?H,#\*Z2D4!0 . *=7R<Y.<G)]3["
MG!0@HKH%%%%26%%%% !1110 4444 %%%% !1110!E>(M3&D>'KZ__BAA8IG^
M\>%_4BOFHDN22V2>23U)KV?XN7_D>'+>S5L-<S@L/55&3^NVO%Z]S+*=J;GW
M/GLTJ<U50[!1117J'F'>?"S0QJ.OMJ$J9@L0&7/0R'[OY#)_*O;JY+X<:7_9
M?@ZU9UQ+=9N'_P"!?=_\= KK:^9QE7VE9OHCZC TO9T4NKU%HHHKE.P****
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MYN9QO13[,]+*I6K-=T>A4445X)]$%%%% !1110 4444 %%%% !1110 4444
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M_P#V='_"F#_T'O\ R3_^SKU:BCZ_B/YOP0?V?A_Y?Q9Y3_PI@_\ 0>_\D_\
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M 4444 %%%% !114<DB0Q-)(P5%!9F/  [F@#ROXPZH"^GZ4K?=S<2#_QU?\
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MO]XC\_R/5Z***^</J HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAT;2;73X/]7!&$!]3W)^IYKS,RK\L%377\CT\LH<]3G>R-"BBBO"/H0HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 5RWB3XH:?IRM;Z3MOKKIO'^J4_7^+\./>O(M3U6^UB^:[O[AYIF[GH!Z =
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M_M5OK&:W;I(I /H>QKBIRY9)G1B*?M*;B>6T4Z5&BD:-QAT)5AZ$=:;7IGS
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MRV/I,-AH4(V6XM%%%<YTA1110 4444 ?/WQ'_P"1^U3ZQ?\ HI:Y6NJ^(_\
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M_P!=W_G7A?8U[I\*_P#D2X_^N[_SKSLS_@KU/1RK^/\ ([>BBBO /HPHHHH
M**** "BBB@ HHHH **** "BBB@!*J:K_ ,@F\_ZX/_Z":MU4U7_D$WG_ %P?
M_P!!-./Q(F?PL^8****^N6Q\:]PKU3X,?>UOZ0?^U*\KKU3X,?>UOZ0?^U*X
M\P_W=_+\SLR[_>(_/\CU>BBBOG#Z@**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^'WOTKF;BTN;.3R[F"6!_P"[*A4_D:[X583^%W//G1J0^)6(J***U,PHHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1=)MM/MQ\D*;<GJQ[D_4\UHT45XC;;NSWHI122%HHHI%!1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"8?V,-=WN+1117,=84444 %%%% !1110 4444 )7F'QBM"]EI=Z!Q'*\1/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJHJJJX4< #M3Z^[P6"AA::C'?JSYS$5Y5I\TA:***[3 **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 )63KVEC4[ A1^_CRT9]_3\:UZ2G&3B[H32:LSR8@@D$8(X(
M-=OX/?=I,BG^&8X^F :RO%>F?9[H7L8Q%*<.!V;_ .O5_P %D?9;H=Q(I_,5
MVU9*=+F1QTXN-2S.HK@_%T>W60W]^)3^.2/Z5WAZ5Q/BV.276;>-1DO&JK[L
M6/%84/C#'QO1^9L>$[;R='$A',SEOPZ#^59OC.^_U%DI_P"FC_T_K73P1I8V
M"(6Q'#&!N/H!UKS34;QK_4)KEOXV^4>@'0?E7SV?XODHN"WE^1[&48;57VBO
MQ*U%'-=5H/AAI-MW?IA.J0GOZ%O\*^3PF$J8F?)37_ />KUX48\TBOH'AUKU
MDNKM=MN.50\%_P#ZU=PJA%"J,*. !VIP&.!2U]S@L%3PL.6._5GSM?$3K2YI
M"T445VF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 0S017,#PS1K)$X*LK#((]Q7DWBSX7S0-)>Z"IEBZM:$Y9?]TGJ/8\_6O7J*
MVH8B=&5X,YZ^'A6C:2/E=T>*1XY$9'4D,K+@@CJ"*;7T5X@\':1XC0FZ@"7&
M,+<1_*X_'N/K7EFN?#'6M++2V2C4+<<_N^) /=>_X$U[=#,*=326C/"Q&7U:
M>L=4<113YH9()FBFC>.13AD8%6!]Q3*[[G!:P4444 %%%% !1110 4444 %%
M%% !15FQL+S4IA#96LMQ(>T:%C^/I7>Z'\)K^Y99=8G%I%WBB(>0_C]T?K6%
M3$4J2]YFU+#U:KM%'GUM:SWMPL%M"\TSG"QH"S$^PKU3PI\+1$T=[K^UW'S+
M:*<J#_MGO]!Q7=:+X<TOP_!Y6GVJ1DC#2$9=OJW6M>O(Q.82G[L-$>UALMC"
MTJFK&(BQ($10J*  H& !]*DHHKS3U HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU@BAB'18T"@?@*GHHS7->^YU)6T0M%%% PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *BEC6:%XVSM<%3C@X-244FDU9@0P6\5M&(H8U
M1%Z*HP*FHHH225D#;;NQ:***8!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>gern-20241101.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-11-06T20:54:20.1603+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.geron.com/20241101" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:gern="http://www.geron.com/20241101" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.geron.com/20241101/taxonomy/role/Cover" id="Cover">
        <link:definition>100000 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.geron.com/20241101/taxonomy/role/Cover" xlink:href="gern-20241101.xsd#Cover" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241101/taxonomy/role/Cover" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46506890215552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  01,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">000-20859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GERON CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000886744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">75-2287752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">919 E. HILLSDALE BLVD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">SUITE 250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">FOSTER CITY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">473-7700 <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GERN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MP %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ HSAG69>*NQS     $P(
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M_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ HSAG620>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( *,X9UEED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    " "C.&=9)7(?WNX    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "C.&=9
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( *,X9UG\%;E@;00  #01   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "C.&=9
MGZ ;\+$"  #B#   #0              @ &P#   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( *,X9UF7BKL<P    !,"   +              "  8P/  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( *,X9UFJQ"(6,P$  "("   /
M      "  740  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "C.&=9)!Z;
MHJT   #X 0  &@              @ '5$0  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " "C.&=999!YDAD!  #/ P  $P
M    @ &Z$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   $
%%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="gern-20241101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241101/taxonomy/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="gern-20241101.htm">gern-20241101.htm</File>
    <File>gern-20241101.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "gern-20241101.htm": {
   "nsprefix": "gern",
   "nsuri": "http://www.geron.com/20241101",
   "dts": {
    "inline": {
     "local": [
      "gern-20241101.htm"
     ]
    },
    "schema": {
     "local": [
      "gern-20241101.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.geron.com/20241101/taxonomy/role/Cover",
     "longName": "100000 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_6950fb0e-6db0-46f5-a0fe-87d420493a0f",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241101.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6950fb0e-6db0-46f5-a0fe-87d420493a0f",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241101.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIK",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.geron.com/20241101/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000950170-24-122771-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-122771-xbrl.zip
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MV>Q!L_^HPW^]7J=KVS=FNEN'=<9"EL%NP?C']R@S^ERP*(Q&A SI(Z=_V.*
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M?$FGEB14IPV@PJ-6E<,SP,(^8R CPBP=+X/J%8A =#&)XSD9F!7"6P7<$,>
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M;>U]6W/C1K+F\YY?4>NQYZ@C0#;O$B6/8V6UVNX92^HCR7-V]N4$"!3)<H,
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M.-.XS!RO3];'V+_Y+73[ZU^:O<;19E_PVZ3]6:][[(V5O)&^^+YU4&\)>$"
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MH90C/H5>G5;^"M8-.$_\$P1+SL3/;OA%['U_T*OG<WKGV'F@F1A&M\941.(
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M@7\+![7O<5!W.0<M[(S-7L>!U[5W-<T?V61B=R)Q]U.1']MSI':6*N=I"O&
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MHNKD5*.":I)_A>^&0Z[JLI.,N H'^AUZ*?/HE+'"DKPF?[64.91I+FAH:*D
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M*C\BN\]9/C73_ 6+/.44!&@JC1!+(C@,,J&^+K&YTJR-Z:K9@W>G5[=K3D?
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MS3H+/4DBV*E=+(]B&CKEM>Q@5EA$'DQ9G&,9O7!Z2ZW>KY6+FP]3,R7@'J\
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M)Z?BZM?3T^NKS9+G==>?6)TX/1O?3AA9\]!-DR@3?IR1"D?X"GAY+7!G49K
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MWK1A65W?P0K>]"_X'YO1;$:_"3/ZQ_>#R)_]]!\_OA\GD^"G_P]02P,$%
M  @ HSAG69R](>W8$0  &%P   \   !G97)N+65X.3E?,BYH=&WM7&MS%#FR
M_;Z_0A=F=W%$=V,;#(.;(:ZOL>>RPVMMLWOWTPUUE:I;N*I4(ZG<;G[]GDRI
M'MU^ (N-&?!$3-A4J:3,5#Y.IE)^.O-%_NQ/XNE,R10_Q5.O?:Z>[?W?\,F3
MT>;3^^&?&' _CG@Z,>E".+_(U2]W"FFGNMP6LO;FOW11&>MEZ<>53%-=3K?%
MS]7I.->E&LZ4GL[\MM@8W^%54GTBDEPZ]\N=3)^J=#C7J9\-$U-ZB?'VSO(*
MPUQE?IM6:>8.3]9'6[H<\[?;C_GWB3D=.OV!5J?)5.F'>#2.TUBF8FF>\"A,
M=.<9$Q:7;D9X4\7W'X:Z3-7I]O#!N,!LD:GPKC).>VW*;:MRZ?6)ZI,R,395
MEBG!&E6S0@8*:8C:WEBO?$,DKS?F=YDL=+[8/M*%<N*UFHL#4\BR&3@QWIL"
M8[TZ]4.9ZRE6)Y)H$?J^62<QN;';=]?YO_%\IKT:NDHF:KNR:CBWLAJOD'+I
MZE@ZB#S3?ABEC"7W3F=ZHKT(BD,S/'MZO\+_D.GU,IV  &57N?Y</O^ZB]DF
M5O]UX&3IADY9G5W([%_N;CQ:'_?9O&(&'^'3'HND[L2@+J;"V>27._AE:^/A
MPZWU]8?_OSYZ7TWO")G[<Y\W\F V-C8?P2BCZC[:K%@CKX'^3]B@3U7+>2!V
M8O+TRO;O5V5-*7:-A<^29+=BIRQ-729@Z5TEO!$_/7B\)5[I/*>7NA3[=4GN
M0,RUGX'C!:2]$&]GTA92R#*-OQ[33.F)=L:Z:]2.*U#_C6]:_:]0?:Y,6ZQ*
M%!Q[*G[:W%H71:<:4VN<$Y4UB5*I$](CMB$<E--!T!:90*T<*94L!4454CB9
MBY\V-K?Z\Z1JXF]6ICS9B;0:87S;%3+/AXFLW/@+3?6+=$W\,&IVZ*TJIWZF
M2B<F,I?P1L+-E/*D.JZN"%\)O!:)*0IE$PT=RB6<UDR83!S\ZVCOY1M8YM:#
M,6D3#7PW.ARQ=ZH,K='[( [8>S?@GZ:<&O)N\&).B0?BQ2NPZ%_M"V_I(TW:
MGT,35'K?JLSBG;$+42Q4;C+P!VUW U[(8#8K:J=:]W=#PA0_CMY\-4X;%/*M
M1/']-X='>P=B]\71OP:"/LQ&@_/4[IK<VI=MVFMSHHH)C.7Q0&RN;S[\$GNY
M%@)OV("'0W$6I=U[+5TJ?]\6O^X=O%Z#R^GYPJ'S<JK$1)N*L5BB:J\3>"\,
MJ62Y$%(7Y./@3).9+#$T1SB'JUV$?_,[]JZUA1.$2YWDQJ0B(4=LX2=-*C%)
MQ(FIJ#N<V OB;E%B$BPL; 2)Y!8IM(M,EY@*R[@+4:0N09$O( &1 7 Z 8L$
M4RD1>19A#L3+MP,B%!L!G[Z*2Q+I9F(N&9J<Z!2S=-"$5Y-E<-?G 1&A@61.
MI,[E)%<C<03!>(M=@^O'*+RS'(<JJQ$4B :Y/,U9.5S$\Q+9F(AV5'N/69TJ
MM;'XD=1612'R+)\OIM%-^L@_=BIZ92'@2I@]W5S?2,:DCJZ>.*HW$4")IA6,
M'=K#J@%=4J>)JB+<S@U5<Y0M1"6M+Y5U< #'ZM.2.?#:@3,XB&!<3=6'/\IJ
MR];D3*Y3G6D5!BXAN0&9:JZB19(=9KDZU1.=:U  =Q(TFXR0OLUJ#\T?!*[3
ML7!2ITA*DYG*<R(<X<,[4PZ"IPS#GHR=V#N%R5 52OQ#8^FW5CG8?XGE=V=:
M96*_%=>;+,,(.Q*-9/\)#ZIRK?"MG\F -TEH#@@0M";AB8,N@$6X1M]'HQW,
M; %I<!U=<@2WH4XKS -K!;^J)/\"P/@9&/>ST"WYJ%QYQ?+\(GC;;0W1F7/4
MX"]3N""(<R$R.*M 8@3#6'*JH&E88V[L,>TW@(?V^+=5O]?:*E)4-VHV^*8Q
M\ZV3_!Z<Y(I#F_41P%*,7H$#<SQNJAS":T4QMPG>E5RPJB)3#'97(BUU,B<G
ME[5*;R.,RJPIQ./1XZT_,S(HRQH:WWT1D=/6>AOW!^+!:/W\P1/EYTJ52\,#
M;M@8K0/MQ>_IR<9%<P!J$\II1H_$VX8=T+$B+I9"HLA1Z(S=B)Q.K9I*^) @
M#?+LD <[+C^SII[.Q-_J$HYEG:#\@PT(4<(+25'4& WW0T1MC!YM"8TE._ R
M".GR'!"*%SHC[$ +-E:7-9PD?N:KY,;]<BNK;4(VRXNQ(X;W)0]<FIBHGV4(
MPFUV,Z!* I IPD%N*D4 %<$ T30/N!8@$2$VKQU(P",S+P,(XW@TNG5GM^[L
MZC!?$_P=E5';TT8R'*P6@B\946[FR@Z1EAR+5\\/H==0;PRK3%7GG$228L,]
M=:8WDR>4"P(V4B;#<#%6L^8TG3FFN>?2,F AHXKFP""3D!J;TDP5TD,J4Z0\
M!0N.,8$N4\ DGG,D_AG,+P7 0KX>$1! ["370)-^IEV+36>Z"KE.2((Q$*"O
M B)4.;&I+0R/05Y(FBX 9"'W[*@U#+#J4K/-2SK474&7;T&,$2_5U%BKO!R
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M,3 Q+GAS9%!+ 0(4 Q0    ( *,X9UF6-#0K73$   5/ P /
M  "  0$M  !G97)N+65X.3E?,2YH=&U02P$"% ,4    " "C.&=9G+TA[=@1
M   87   #P              @ &+7@  9V5R;BUE>#DY7S(N:'1M4$L%!@
0   $  0 ^    )!P      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>gern-20241101_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gern-20241101.xsd" xlink:type="simple"/>
    <context id="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_42085f00-aa06-4225-ada9-3af899215f34">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_ad4adf5f-24bc-467d-8524-ef8f04e74cab">0000886744</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_19a16dcf-e82c-4736-a3d8-f6a90ae536a4">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_a1f7e529-1d71-40ca-816d-84523cf741af">2024-11-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_8d225a95-eeff-4a72-809c-98624a0eb22a">GERON CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_7e04af0a-ed41-4fc1-821a-355d3c556edb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_26a06eb9-331b-41be-bfe6-5c9b537dae6f">000-20859</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_46d2c521-64a1-46bc-8a0c-0a6cbaaf6458">75-2287752</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_df1483ff-6447-4800-98d8-55cfaf47972b">919 E. HILLSDALE BLVD</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_0d4d85ea-3c05-4fea-a463-8e7c0543ac2a">SUITE 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_0fdfa332-47c0-497d-8084-1f9ca7128a89">FOSTER CITY</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_ae282c90-a710-4e42-9b23-2d4f1dc6c638">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_bef39178-9cc1-46e4-9b8c-723511bb7f7e">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_51f874be-5ca8-4652-acbb-15289de79766">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_e7d8fb00-fcc5-4353-9a32-c6812a240348">473-7700 </dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_bca1c177-6928-4b8b-ba22-a0a9912bffae">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_349d26fc-390e-496a-a274-c6682436be67">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_4292de9f-c549-4343-b227-85f6a9236ba5">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_0240a386-cc42-4c5e-aa36-a7e3284276c5">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_5e2de6e6-8dc9-4d6c-b9c5-01528d2ddfef">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_0dc89aab-cbfc-4a03-a65d-1e54c24beed9">GERN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_839bd2b0-33fa-46d6-ba05-239a91477129">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_6950fb0e-6db0-46f5-a0fe-87d420493a0f"
      id="F_c05722e6-99cc-42b4-b777-10822eb3ab24">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
